Lagrutta, Armando
Regan, Christopher P.
Zeng, Haoyu
Imredy, John P.
Koeplinger, Kenneth
Morissette, Pierre
Liu, Liping
Wollenberg, Gordon
Brynczka, Christopher
Lebrón, José
DeGeorge, Joseph
Sannajust, Frederick
Article History
Received: 11 November 2016
Accepted: 7 February 2017
First Online: 22 March 2017
Competing interests
: All authors are employees at MRL, Merck & Co, in the preclinical safety assessment area or in the pharmacokinetics, pharmacodynamics, and drug metabolism area. Our work, including investigative efforts such as this one, supports development of proprietary preclinical candidates. The authors declare no competing financial interests.